Clinical Trials Logo

Arthritis clinical trials

View clinical trials related to Arthritis.

Filter by:

NCT ID: NCT03881059 Not yet recruiting - Clinical trials for Active Psoriatic Arthritis

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

Start date: March 29, 2019
Phase: Phase 2
Study type: Interventional

The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A or Dose B once daily [QD]) at Week 16 in the treatment of participants with active PsA.

NCT ID: NCT03876210 Not yet recruiting - Arthritis Clinical Trials

Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs

Start date: May 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare the safety and pharmacokinetics of PK101(fixed-dose combination of PK101-001 and PK101-002) with coadministration of the two separate drugs in healthy volunteers.

NCT ID: NCT03863405 Recruiting - Clinical trials for Rheumatoid Arthritis

Metformin Use in Rheumatoid Arthritis

Start date: January 9, 2019
Phase: Phase 2
Study type: Interventional

Metformin has been used clinically for over 50 years, as a glucose lowering agent. Direct and indirect anti-inflammatory effects of metformin have been reported in animal and clinical studies, and this effect is independent of its hypoglycemic effect. Animal studies showed that metformin decreased serum C-reactive protein (CRP) level in atherogenic rabbits and decreased proinflammatory cytokines (interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF-α) in obese mice . Moreover, metformin also suppressed osteoclastogenesis ; this may partially result from decreased expression of inflammatory cytokines that promote osteoclastogenesis in the arthritic joint. The objective of this study is to evaluate the efficacy and safety of addition of metformin to standard disease modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis.

NCT ID: NCT03858504 Not yet recruiting - Clinical trials for Enthesitis Related Arthritis

Yoga Versus Home Exercise Program in Children With Enthesitis Related Arthritis

Start date: March 11, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to compare the effectiveness of different exercises programs as 'Yoga' and 'Home Exercise' in Enthesitis Related Arthritis.

NCT ID: NCT03856190 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Effectiveness of Therapeutic Fasting and Specific Diet in Patients With Rheumatoid Arthritis

NutriFast
Start date: February 27, 2019
Phase: N/A
Study type: Interventional

The aim of this trial is an evaluation of the effectiveness of fasting and a subsequent diagnosis-specific diet change in patients with rheumatoid arthritis in respect to improving rheumatic symptoms and further to investigate possible mechanisms of this improvement.

NCT ID: NCT03855007 Recruiting - Clinical trials for Arthritis, Rheumatoid

The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment

Start date: January 1, 2017
Phase: Phase 4
Study type: Interventional

This study is designed to observed prospectively the efficacy and safety of 6 months treatment of iguratimod alone, or with methotrexate (MTX), hydroxychloroquine (HCQ) and prednisone step by step on Chinese rheumatoid arthritis (RA) and early rheumatoid arthritis (ERA) patients who were naïve or shown insufficiency response or intolerance to DMARDs.

NCT ID: NCT03853395 Not yet recruiting - Clinical trials for Arthritis, Rheumatoid

BIOTIPRA: BIOmarker-guided Treatment Decisions In Psoriatic and Rheumatoid Arthritis

BIOTIPRA
Start date: February 2019
Phase: N/A
Study type: Interventional

TNFi drugs remain the most prescribed first-line biologics for patients with rheumatoid arthritis (RA) and Psoriatic Arthritis (PsA). However, up to 40% of RA patients fail to respond to TNFi treatment. One explanation of non-response is the development of anti-drug antibodies and low drug levels. Studies have consistently shown that: 1. Drug levels of monoclonal antibodies (e.g. adalimumab/certolizumab) and the presence of anti-drug antibodies in samples taken at 3 and 6 months correlate with 12 month response. 2. Non-responders and those who develop anti-drug antibodies are less likely to receive concomitant methotrexate or, if they do receive it, are on lower doses than responder groups. However, it has not been proven that knowing that a patient has low drug levels or anti-drug antibodies improves the outcome; neither has it been shown that introducing or increasing the dose of methotrexate would reduce the formation of anti-drug antibodies, thereby improving outcome. Observational data has revealed that RA non-responders, who exhibit adequate serum drug levels and no detectable anti-drug antibodies, have lower probability of response to another agent with the same mechanism of action (MOA). RA and PsA non-responders, who have low detectable serum trough levels and detectable anti-drug antibodies, may benefit in switching to a less immunogenic drug. The next essential step, therefore, is to prove that introducing these tests improves clinical outcome. The proposed trial is a clinical feasibility trial with the aim to ensure a realistic assessment and capability to conduct the full clinical trial. Participants with RA or PsA, commencing adalimumab or certolizumab will be randomised to determine whether providing test results on trough drug levels and anti-drug antibodies at 4 weeks, 3 and 6 months to clinicians caring for patients with RA or PsA (n=15 patients) starting treatment with adalimumab/certolizumab, improves the course of disease activity, compared to standard care (n=15 patients). Clinicians will be provided with feedback and a treatment algorithm. The feasibility of the study will be assessed by a number of factors including evaluation of recruitment, attrition, data completeness and process evaluation.

NCT ID: NCT03852355 Recruiting - Clinical trials for Rheumatoid Arthritis

the Effectiveness of 3rd Occipital Radiofrequency Versus Systemic Steroid in Headache Management in Rheumatoid Arthritis

Start date: February 25, 2019
Phase: N/A
Study type: Interventional

Rheumatoid arthritis is a common type of autoimmune arthritis that is characterized by inflammation of the synovial membranes. Even though any joint can be affected by the disease, cervical spine is often affected, and cervical pain is reported by 40-88% of RA patients, Cervical spine involvement is a feature of long-lasting disease, where atlantoaxial impaction with odontoid process vertical subluxation through the foramen magnum being one of the greatest and dangerous complications

NCT ID: NCT03850392 Completed - Cryotherapy Effect Clinical Trials

Anti Inflammatory Effects of Local Cryotherapy in Knee Arthritis

ALGGAR
Start date: February 12, 2013
Phase: N/A
Study type: Interventional

47 patients with non-septic knee arthritis were treated by local ice (30 min) or cold CO2 (2 min) twice at an 8 hour-interval for 1 day. The synovial fluid was collected just before the first cold application then 24 hours later. Cytokine, VEGF, NF-kB, PG-E2 levels were assessed in the synovial fluid before/after treatment. Contralateral arthritic knees were used as paired controls when possible.

NCT ID: NCT03843619 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Electronic and Lab Pre-screening of New Rheumatology Patients With Rheumatoid Arthritis

Start date: February 28, 2019
Phase:
Study type: Observational

By forming the foundation of a delivery system that integrates primary care (PC) and rheumatology, this initiative strives to strengthen the roles of both primary care and rheumatology practices as they co-manage patients in a quality care delivery system. Importantly, it strives to fill an unmet need, the rapid evaluation by Primary Care providers; the appropriate and timely referral of inflammatory disease patients to a rheumatologist; and the implementation of early aggressive therapy in the management of patients with rheumatoid arthritis (RA) with tight control. Given the call for improved quality, value, and demonstration of results[1], this initiative uses the tenets of National Center for Quality Assurance's Patient Centered Specialty Program[1] (PCSP) and it successfully masters and streamlines coordination of care.